KIMS to acquire 3,000 beds in next 5 years in Kerala
The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode
The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
US Generics grew 5% to Rs. 467 Crores for the quarter
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
Subscribe To Our Newsletter & Stay Updated